

T.E. King Jrs's institution has received fees for consultancy work or for work on an advisory committee from InterMune, Actelion, Gilead, ImmuneWorks, and Genzyme, and has received grants from the NIH for the IPFnet study.

L. Richeldi has received consulting fees from Boehringer Ingelheim, Intermune, Celgene, Anthera, GlaxoSmithKline and Gilead. He has also received and lecture fees from Intermune and Boehringer Ingelheim.